Exelixis (EXEL) Gains from Investment Securities (2014 - 2019)
Exelixis' (EXEL) quarterly Gains from Investment Securities came in at $730000.0 in Q2 2019, up 249.28% quarter-over-quarter from $209000.0 in Q1 2018.
Exelixis (EXEL) Gains from Investment Securities (2014 - 2019) Analysis & Trends
Exelixis' Gains from Investment Securities history runs 6 years deep, the most recent figure standing at $730000.0 for Q2 2019.
- On a quarterly basis, Gains from Investment Securities changed N/A year-over-year to $730000.0 in Q2 2019; TTM through Sep 2019 was $730000.0, a 249.28% increase from a year earlier, with the FY2018 full-year figure at $209000.0, down 92.99% from the prior year.
- Gains from Investment Securities improved to $730000.0 in Q2 2019 per EXEL's latest filing, from $209000.0 in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $2.5 million in Q3 2016 and bottomed at $209000.0 in Q1 2018.
- The 5-year median for Gains from Investment Securities is $730000.0 (2019), against an average of $1.3 million.
- Across the five-year window, Gains from Investment Securities jumped 131.57% in 2015 and retreated 6.13% in 2017, its largest moves.
- Year by year, Gains from Investment Securities stood at $549000.0 in 2015, then surged by 254.28% to $1.9 million in 2016, then climbed by 20.36% to $2.3 million in 2017, then tumbled by 91.07% to $209000.0 in 2018, then jumped by 249.28% to $730000.0 in 2019.
- Per Business Quant, the three latest EXEL Gains from Investment Securities figures stand at $730000.0 (Q2 2019), $209000.0 (Q1 2018), and $2.3 million (Q3 2017).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Exelixis | 14.44 Bn | 13.66 Bn | 590.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2019 | 730,000.00 |
| Jun 28, 2019 | 730,000.00 |
| Mar 30, 2018 | 209,000.00 |
| Mar 30, 2018 | 209,000.00 |
| Sep 29, 2017 | 2.34 Mn |
| Sep 29, 2017 | 2.34 Mn |
| Jun 30, 2017 | 639,000.00 |
| Jun 30, 2017 | 639,000.00 |
| Dec 30, 2016 | 1.95 Mn |
| Dec 30, 2016 | 1.95 Mn |
| Sep 30, 2016 | 2.49 Mn |
| Sep 30, 2016 | 2.49 Mn |
| Mar 31, 2015 | 549,000.00 |
| Mar 31, 2015 | 549,000.00 |
| Dec 31, 2014 | 76,000.00 |
| Dec 31, 2014 | 76,000.00 |
| Sep 30, 2014 | -62,000.00 |
| Sep 30, 2014 | -62,000.00 |
| Jun 30, 2014 | -115,000.00 |
| Jun 30, 2014 | -115,000.00 |